Analystreport

CRISPR Therapeutics AG (NASDAQ: CRSP) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $53.00 price target on the stock.

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time